Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJM197401242900418 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A descriptive summary of the WHO availability assessments of medical abortion medicines in eight African countries.
Reprod Health
December 2024
UNDP‑UNFPA‑UNICEF‑WHO‑World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research, World Health Organization, 20 Avenue Appia, 1211, Geneva, Switzerland.
Background: The use of medical abortion using either a combination of mifepristone and misoprostol, or misoprostol alone has contributed to increased safety and decreased mortality and morbidity. The availability of quality medical abortion medicines is an essential component in the provision of quality abortion care. Understanding the factors that influence the availability of medical abortion medicines is important to help in-country policymakers, program planners, and providers improve availability and use of medical abortion.
View Article and Find Full Text PDFOutcomes After Early Pregnancy Loss Management With Mifepristone Plus Misoprostol vs Misoprostol Alone.
JAMA Netw Open
October 2024
Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor.
Importance: Medication management of early pregnancy loss (EPL), or miscarriage, typically involves the administration of misoprostol with or without pretreatment with mifepristone. Combination treatment with mifepristone plus misoprostol is more effective than misoprostol alone but is underutilized in the US.
Objective: To describe differences in clinical outcomes after EPL management with mifepristone plus misoprostol vs misoprostol alone using commercial claims data.
Prostaglandin E1 in neonatal pulmonary hypertension: Need for randomized trials based on physiology-Response.
Pediatr Pulmonol
January 2025
Department of Pediatrics, University of California San Francisco, UCSF Benioff Children's Hospital, San Francisco, California, USA.
Likely Connection Between Increased Production and Release of Prostaglandin-E2 (PGE2) by Human Granulosa Cells From Polycystic Ovaries and Pyroptosis.
Am J Reprod Immunol
September 2024
Department of Molecular Biology and Genetics, Tokat Gaziosmanpasa University, Tokat, Türkiye.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!